Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TNKS | O95271 | 2/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22506075 | 0.85 | MAPT (0.37) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL15497424 | 0.80 | GPR3 (0.68) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL23729525 | 0.79 | GPR3 (0.54) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL355686 | 0.79 | GPR3 (0.54) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL24723524 | 0.77 | GPR3 (0.42) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL22011432 | 0.76 | TNKS (0.46) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL22147017 | 0.76 | MAPT (0.54) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL24889416 | 0.76 | GPR3 (0.50) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL1294718 | 0.76 | GPR3 (0.50) | GPR3MAPTTNKSTNKS2ALOX5 | |
| SCHEMBL10122734 | 0.76 | GPR3 (0.50) | GPR3MAPTTNKSTNKS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11706982-B2 | Fused polycyclic compound, and preparation method and use thereof | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| US-11706982-B2 | Fused polycyclic compound, and preparation method and use thereof | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| US-20200343455-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | NINGBO LUMILAN ADVANCED MATERIALS, CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200343456-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | NINGBO LUMILAN ADVANCED MATERIALS CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200343456-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | INTS9, INF2, CYBA | GPR3 2505/4885MAPT 1059/4885TNKS 2827/4885 |
| US-11706982-B2 | Fused polycyclic compound, and preparation method and use thereof | INF2, INTS9, PYM1 | GPR3 2308/4885MAPT 955/4885TNKS 2686/4885 |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | GPR3 3584/4885MAPT 3187/4885TNKS 3289/4885 |
| US-20200343455-A1 | Fused Polycyclic Compound, and Preparation Method and Use Thereof | INF2, INTS9, PYM1 | GPR3 2308/4885MAPT 955/4885TNKS 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.